{
    "nct_id": "NCT05681481",
    "official_title": "An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long Term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid",
    "inclusion_criteria": "* Has completed the week 36 visit of ARGX-113-2009\n* Is capable of providing signed informed consent and complying with protocol requirements\n* Agrees to use contraceptive measures consistent with local regulations and the following: Women of childbearing potential must have a negative urine pregnancy test at baseline before receiving the study drug and must use one of the contraception methods described in the protocol from signing the ICF until the last dose of the study drug\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Clinically significant disease, recent major surgery (within 3 months of baseline), or intends to have surgery during the study; or any other medical condition that, in the investigator's opinion would confound the results of the study or put the participant at undue risk\n* Known hypersensitivity to the study drug or 1 of its excipients\n* Permanently discontinued IMP in ARGX-113-2009 due to an adverse event (AE) considered related to the study drug and for whom the benefit/risk balance is not considered positive",
    "miscellaneous_criteria": ""
}